Previous studies showed that a proportion
of normotensive Sprague-Dawley rats spontaneously
exhibit lower baroreflex sensitivity.
However, investigations have not yet been carried
out on Wistar rats. We aimed to compare
baroreflex sensitivity among rats from the
same strain and the same laboratory. Male
Wistar normotensive rats (300-400g) were
studied. Cannulas were inserted into the
abdominal aortic artery through the right
femoral artery to measure mean arterial pressure
and heart rate. Baroreflex was calculated
as the derivative of the variation of heart rate
in function of the mean arterial pressure variation
(ΔHR/ΔMAP) tested with a depressor
dose of sodium nitroprusside (50 μg/kg) and
with a pressor dose of phenylephrine (8μg/kg)
in the right femoral venous approach through
an inserted cannula. We divided the rats into
four groups: i) high bradycardic baroreflex,
baroreflex gain less than -2 tested with
phenylephrine; ii) low bradycardic baroreflex,
baroreflex gain between -1 and -2 tested with
phenylephrine; iii) high tachycardic baroreflex,
baroreflex gain less than -3 tested with
sodium nitroprusside; and iv) low tachycardic
baroreflex, baroreflex gain between -1 and -3
tested with sodium nitroprusside.
Approximately 71% of the rats presented a
decrease in bradycardic reflex while around
half showed an increase in tachycardic reflex.
No significant changes in basal mean arterial
pressure and heart rate, tachycardic and
bradycardic peak and heart rate range were
observed. There was a significant change in
baroreflex sensitivity among rats from the
same strain and the same laboratory.
Baroreceptors, hypertension, autonomic nervous system, parasympathetic nerve, sympathetic nerve.
Vitor E. Valenti, Departamento de Medicina, Disciplina de Cardiologia, Universidade Federal de São Paulo, UNIFESP, Rua Napoleão de Barros, 715 – Térreo, 04039- 032, São Paulo, SP, Brazil. Tel. +55.11.5572-5462. E-mail: vitor.valenti@gmail.com
This research was supported
by public funding from Fundação de Amparo Ã
Pesquisa do Estado de São Paulo (FAPESP).
2011-05-09T00:00:00

Trending Topic
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1 Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in low- and middle-income countries (LMICs), where over three-quarters of all cases now occur.2 The condition’s […]
Hypertension is the leading modifiable risk factor for global cardiovascular disease, responsible for an estimated 10.8 million deaths and more than 200 million disability-adjusted life years annually.1Â Despite the availability of effective pharmacological and lifestyle interventions, prevalence continues to rise, particularly in ...
Hypertension affects over 1.4 billion adults worldwide and remains the leading modifiable risk factor for global cardiovascular (CV) morbidity and mortality. It is responsible for an estimated 10.8 million deaths annually and contributes significantly to the global burden of ischaemic heart disease, ...
Hypertension has been associated with increased cardiovascular morbidity and mortality, as well as with overall elevated all-cause mortality.1 Prevalence increases with age, affecting 28.5% of US individuals aged 20–44 years, 58.6% of those aged 45–64 years and 76.5% of those aged 65 years and older.2 In ...
Hypertension (HTN) is one of the largest contributors to cardiovascular (CV) morbidity and mortality in the USA and is estimated to affect 47% of the adult population or approximately 122 million adults older than 20 years of age.1Â Recent estimates suggest that over 40% ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Hypertension is a global health problem, with an estimated 1.13 billion individuals affected.1 Patients with hypertension, especially when resistant to conventional therapy, are at high risk of sequelae, e.g., ischaemic heart disease, haemorrhagic and ischaemic stroke, cardiac failure, peripheral vascular ...
Keep track of your clinical interests and newsletter subscriptions.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Already registered? Login below.